Conference on Management of Hepatitis C
NIH is sponsoring a Consensus Development Conference on Management of Hepatitis C, chaired by Dr. Donald W. Powell of the University of Texas Medical Branch at Galveston, in Natcher Conference Center Mar. 24-26.
The hepatitis C virus (HCV) is a major cause of both acute and chronic hepatitis in the United States. Hepatitis C, previously known as "non-A, non-B hepatitis," affects between 1 and 2 percent of Americans, and chronic infection with HCV is probably the single most important cause of chronic liver disease, cirrhosis, and liver cancer in the Western world. Not all cases of hepatitis C are severe or progressive. Many patients are asymptomatic and are only diagnosed when they are found to have abnormal liver tests following a blood donation or routine evaluation for another problem.
There are presently no specific ways to prevent hepatitis C. Alpha interferon has been approved for treating hepatitis C. The conference will evaluate the existing scientific data and deliberate on how patients should be managed.
The final consensus statement will be presented at a press conference at 1 p.m. on Wednesday, Mar. 26 at Natcher auditorium. The conference is sponsored by NIDDK and OMAR, with support from NIAID, NHLBI, and the Centers for Disease Control and Prevention. For more information, call (301) 770-3153, or email confdept@tech/res.com, or access the WWW site at http://consensus.nih.gov.
Up to Top